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Abstract
Rhabdomyolysis, if severe, can lead to acute kidney injury 
(AKI). Myoglobin is an iron and oxygen-binding protein that 
is freely filtered by the glomerulus. Precipitation of myoglo-
bin in the nephrons’ distal parts is responsible for tubular 
damage with AKI as a consequence. Extracorporeal clearance 
of myoglobin is conventionally attempted by the use of con-
tinuous renal replacement therapy (CRRT) with high cut-off 
dialysis membranes to limit the extent of the damage. We 
describe a case of a 56-year-old man with traumatic crush in-
jury and a persistent source of muscle ischaemia unrespon-
sive to high dose CRRT with EMiC-2 filter. Due to therapy fail-
ure, he was subsequently treated with the addition of a hae-
moadsorber (CytoSorb®) to the circuit. This reduced 
myoglobin and creatine kinase levels successfully despite on-
going tissue ischaemia. However, CytoSorb® was not enough 
to maintain microcirculatory perfusion, resulting in the even-
tual demise of the patient due to severity of the injury. Our 
report indicates that myoglobin was efficiently removed with 
CytoSorb® following exchange with the conventional high 
cut-off filter in continuous venovenous haemodialysis in se-
vere traumatic rhabdomyolysis. © 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Rhabdomyolysis is caused by the destruction of stri-
ated muscle cells and subsequent release of large quanti-
ties of intracellular contents to the circulation, including 
myoglobin, electrolytes and enzymes [1]. Myoglobin, 
which is an iron-containing protein weighing 17.8 kDa, 
is the primary nephrotoxic molecule being released in 
rhabdomyolysis [2]. Renal tubular obstruction, oxidative 
injury and vasoconstriction of the renal artery are the 
proposed mechanisms held responsible for the cause of 
renal injury [2]. Combined with hypovolemia and meta-
bolic acidosis, myoglobinuria may lead to acute kidney 
injury (AKI) [3]. More than fivefold increased creatine 
kinase (CK) levels are generally used as a surrogate for 
diagnosis of rhabdomyolysis [4–6].
Restricting the damage associated with myoglobinuria 
is fundamental in treatment [4]. Continuous renal re-
placement therapy (CRRT) with high cut-off protein per-
meable filter properties is conventionally used to clear 
myoglobin from the blood [7].
CytoSorb® (Cytosorbents Corporation, Monmouth 
Junction, NJ, USA) is a haemoadsorption device capable of 
removing molecules weighing between 10 and 55 kDa in-
cluding pro-inflammatory cytokines and myoglobin from 
the blood. It can be used as part of a CRRT circuit [8, 9].
Inflammatory mediators such as cytokines underline 
microcirculatory and parenchymal cell damage. Micro-
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circulatory alterations are associated with organ failure, 
such as AKI [10]. They can be observed by sublingual mi-
crocirculation using handheld vital microscope.
Here we present a case study of fatal rhabdomyolysis 
first treated with CRRT and high cut-off filter and later, 
along with a CytoSorb® adsorber for reasons of therapy 
failure. The effects of the therapies on sublingual micro-
circulation are monitored by handheld vital microscopy.
Case Report
This case report describes a 56-year-old male patient, without 
any previous confirmed medical diagnosis, who suffered severe 
traumatic rhabdomyolysis of the lower extremities and abdominal 
wall due to a crush injury.
The patient was awake at the trauma scene. His hypotension 
and tachycardia were treated with intravenous fluids. Examination 
in the Emergency Department revealed a hematoma in the pelvic 
region and ischaemic lower extremities without any arterial pulse 
signals. Abdominal computed tomography showed a traumatic 
dissection of the distal aorta and both arteria iliaca, as well as a bi-
lateral transection of the vena femoralis. Also, laboratory diagnos-
tics showed severe rhabdomyolysis, indicated by myoglobin levels 
of 79,931 µg/L and CK levels of 15,032 U/L.
The patient was rushed to the Operating Room in an attempt to 
re-establish arterial supply to the lower extremities. Left arteria fem-
oralis communis and arteria iliaca externa were reconstructed with 
a synthetic graft. Femoral-femoral crossover construction with a 
graft from left to right was performed after unsuccessful recanaliza-
tion of the left iliac artery. Although technically successful, function-
ality lacked due to persistent ischaemia of > 6 h. Lactate was 6 mmol/L. 
Bilateral guillotine amputation above the patella was performed.
The patient was postoperatively transferred to the intensive 
care unit (ICU), and treated with mechanical ventilation and ad-
ministration of high-dose noradrenaline ranging between 0.6 and 
0.8 µg/kg/min. Broad-spectrum antibiotics were initiated. CRRT 
with Continuous Veno-Venous Hemo-Dialysis mode was initiat-
ed with a high-cut off EMIC-2 dialysis filter (Fresenius Medical 
Care, Bad Homburg, Germany) to remove excess myoglobin from 
the bloodstream. The settings were as the following: Blood flow 
rate: 200 mL/min, Dialysate flow rate: 4,000 mL/h, Prescribed Re-
nal Dose: 50 mL/kg/h (patient weight: 80 kg). No anticoagulation 
was employed due to severe shock and deranged coagulation pa-
rameters (international normalized ratio > 10 and activated partial 
thromboplastin time > 180 s). Evolution of the kidney functions 
and myoglobin and CK levels can be seen in Figures 1 and 2 during 
this phase.
The fluid balance for the first day was +14,000 mL, and average 
noradrenaline demand was 1 µg/kg/min. To guide fluid and vaso-
active drug therapy, continuous cardiac output monitoring by use 
of transpulmonary thermodilution (PiCCO®) device was applied. 
Six packs of red blood cells were transfused. Sublingual microcir-
culation measurement showed a rich and mostly perfused vessel 
density, which was analyzed by dedicated software [11]: total vessel 
density (TVD): 22.73 mm/mm2, percentage of perfused vessels 
(PPV): 0.93 (online suppl. Video 1; for all online suppl. material, 
see www.karger.com/doi/10.1159/000505899). As the patients’ 
status did not improve, and neither myoglobin nor potassium lev-
els could not be lowered, a re-exploration surgery was performed, 
and the vitality of the tissues was assessed. A subsequent laparoto-
my revealed sigmoid ischaemia, and in response, a proctosigmoid-
ectomy was executed.
Despite the literature [5, 7], the EMIC-2 filter alone was not able 
to prevent progressive myoglobin increase following this proce-
dure. In response, a CytoSorb® adsorber was added to the circuit 
instead, as shown in [12], on the second day of the ICU stay. 
 Myoglobin levels were lowered significantly from 110,000 to 90,000 
µg/L as well as CK levels from 115,000 to 65,000 U/L within 4 h of 
CytoSorb® treatment. Rapid saturation of the adsorber was noticed 
necessitating a change of adsorber after 12 h of initiation. After 
Cyto Sorb® replacement, levels again were reduced from 110,000 to 
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Fig. 1. Evolution over time of myoglobin 
level and CK levels during CRRT with 
EMIC-2 and CRRT with EMIC-2 plus 
 CytoSorb in series. CK, creatine kinase.
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70,000 µg/L within 12 h. However, noradrenaline consumption 
could not be lowered, ranging between 1.15 and 1.25 µg/kg/min. 
The fluid balance was +9,900 mL. This inquired another re-explo-
ration revealing rectum stump ischaemia. Three packs of red blood 
cells were transfused. Sublingual microcirculation measurement 
was similar to day 1 with a TVD of 23.53 mm/mm2 and PPV of 0.99. 
The patients’ condition deteriorated further on day 3. Nor-
adrenaline consumption hit the highest level of 1.75 µg/kg/min 
and could only be lowered to a minimum of 1.15 µg/kg/min with 
the help of a renewed CytoSorb® adsorber. Enoximone 1 µg/kg/
min and Amiodarone 600 mg over 24 h were initiated to no avail. 
Another laparotomy showed total avital rectus abdominis muscles. 
No further treatment was possible. Despite this unresolved source, 
myoglobin levels were reduced from 90,000 to 50,000 µg/L and CK 
65,000 to 40,000 U/L. Sublingual microcirculation ceased to flow 
hours before patients final demise: TVD: 12.46 mm/mm2 PPV: 
0.06 (online suppl. Video 2). Parallel to this, lactate levels did not 
normalize. Haemodynamic parameters and blood values associ-
ated with the case are shown in Table 1.
Discussion
Severe rhabdomyolysis often results in myoglobinuria 
and AKI. High volume CRRT with high cut-off protein 
filters can be employed to restrict ensuing damage, al-
though this only affects myoglobin levels and not CK. De-
spite the application of a high cut-off EMiC-2 dialysis fil-
ter with a high blood and dialysate rate, myoglobin levels 
were not reduced significantly, and CK levels increased 
massively. Blood purification with haemoadsorption has 
been shown to filter non-specifically pro-inflammatory 
molecules from the bloodstream. Also, myoglobin has 
been shown to be filtered in an animal model of smoke 
and burns injury [13]. 
Our report shows that the use of CytoSorb® in this 
severe rhabdomyolysis patient was successful in reduc-
ing plasma concentrations of myoglobin and CK de-
spite an unresolved source of bowel ischaemia and un-
noticed abdominal wall ischaemia. Furthermore, the 
CytoSorb® adsorber was shown to be more successful 
at eliminating myoglobin and CK than conventional 
EMiC-2 filter. An adsorber change per 12 h or even ear-
lier seems plausible in severe cases to ensure continuous 
mediator reduction.
One could argue that, the demise of the patient could 
have been the consequence of severe shock which could 
not be fully resuscitated as indicated by the low cardiac 
index and high lactate levels. Normalization of the mac-
rohaemodynamic indices was attempted by use of fluids, 
vasopressors and vasoactive agents in our patient. The 
high lactate levels despite the resuscitation can be both 
due to unresolved source and/or flow heterogeneity with 
oxygen extraction deficit that is seen in patients with sep-
tic shock [14]. Although, hyperlactatemia is valuable in 
the initial phases of shock, haemodynamic coherence 
rapidly disappears over hours and limits lactate usage in 
prolonged shock [15]. Additionally, we did not detect any 
flow heterogeneity in the sublingual microcirculation 
measurement of the patient in the first 2 days of the ICU 
stay. It is our interpretation that in this initial phase of 
systemic haemodynamic compromise, regulatory mech-
anisms at the regional level were still able to keep the mi-
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crocirculation perfused. However, following persistent 
depressed macrocirculation, the microcirculation could 
no longer be sustained and the alterations we observed set 
in, followed by the unfortunate death of our patient.
Additionally, our report shows that myoglobin can sig-
nificantly affect not only the renal perfusion but also sys-
temic tissue perfusion, but the outcomes of this effect may 
take time to develop. Myoglobin has a considerably lower 
oxygen half saturation (p50) compared to haemoglobin 
(2.8 vs. 26 mm Hg) and impairs tissue oxygenation by 
strongly binding to oxygen [16]. Myoglobin also increases 
vascular resistance, impeding perfusion further [17]. Thus, 
excess myoglobin can affect 2 determinants of microcircu-
latory and tissue perfusion, that is, convection and diffu-
sion of oxygen. Persistence in such a condition as in our 
case, led to the eventual deterioration of the microcircula-
tion too, suggesting that the timing of CytoSorb® applica-
tion may have been critical and that in such conditions ear-
ly application of CytoSorb® may be indicated to avoid the 
progression from normal to abnormal microcirculation.
Lastly, there was a discrepancy in the trends of urea 
and creatinine levels during CRRT. CRRT was successful 
in reducing the urea concentration but not the creatinine. 
Previous studies reported a parallel reduction in both 
[18–20]. This may have been on account of ongoing mus-
cle destruction.
In summary, this study shows that the haemoadsorb-
tion with the CytoSorb® adsorber improves both myo-
globin and CK clearance compared to the initial high dose 
CRRT with EMiC-2 filter. Treatment with CytoSorb® 
improved the microcirculatory perfusion at day 2 of the 
ICU stay, despite abnormal macrohaemodynamic pa-
rameters showing a loss of haemodynamic coherence. 
However, injuries were so severe that just the removal of 
myoglobin and CK did not result in survival at day 3. This 
report underscores our opinion the need to install the ad-
sorber in an early phase for removal of inflammatory cy-
tokines and myoglobin.
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Table 1. Hemodynamic and blood values
Day 1 Day 2 Day 3
Lactate, mmol/L 5.1 10.1 7.8
ScvO2, % 65 81 69
Mean arterial pressure, mm Hg 70 70 65
Cardiac index, L/min/m2 3.1 1.9 –
Heart rate, bpm 117 131 100
Hemoglobine, g/dL 4.6 5.5 5.2
Fluid balance, mL/day +14,000 +9,900 +2,300
TVD, mm/mm2 22.73 23.53 12.46
PPV, % 93 99 6
Myoglobin*, µg/L 79,931 110,000 90,000
CK*, U/L 15,032 115,000 65,000
Total bilirubine*, μmol/L 6 12 24
Alanine transaminase*/aspartate transaminase*, U/L 24/30 3,457/8,850 1,869/4,950
SOFA score 16 14 18* Peak values are shown.
ScvO2, central venous oxygen saturation; TVD, total vessel density; PPV, percentage of perfused vessels; CK, 
creatine kinase.
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